Our expert for hiPSC derived cardiac cells, and cell-based assays & services for drug safety and efficacy screenings
The use of Cor.4U® and Pluricyte® Cardiomyocytes in combination with the Maestro™ MEA system has been optimized extensively. Combining these technologies enables detailed electrophysiological detection of potential cardioactive and proarrhythmic effects of test compounds in 48- and 96-well plate formats.
Cor.4U® and Pluricyte® Cardiomyocytes in combination with the Maestro™ MEA system provide a highly relevant in vitro assay platform to study the cardiac safety or efficacy profile of compounds during drug development.
You can find our recommendations on how to combine our cardiomyocytes with the Maestro™ MEA system on 48- and 96-well plate formats for electrophysiology measurements in the following User Guides:
Case studies were performed to assess the effects of cardioactive compounds on the electrophysiology of Cor.4U® and Pluricyte® Cardiomyocytes using the Maestro™ MEA system. Both Pluricyte® Cardiomyocytes and Cor.4U® Cardiomyocytes show the expected pharmacological responses to reference compounds in a reproducible manner. Below, an example is shown of the effect of the reference compound, E4031, in Cor.4U® Cardiomyocytes.
E4031 induced a prolongation in the field potential duration of Cor.4U® Cardiomyocytes
E4031 is a hERG channel blocker that is expected to delay the repolarization phase, resulting in a prolonged field potential duration (FPD) and ultimately proarrhythmic events. The induced concentration-dependent increase of the FPD in Cor.4U® Cardiomyocytes is shown here (first panel) by an overlay of averaged field potential waveforms. At concentrations of 100 nM E4031, TdP-like arrhythmias were observed (second panel).